Avalo Therapeutics (AVTX) Net Margin (2016 - 2025)
Avalo Therapeutics' (AVTX) quarterly Net Margin came in at 23254.24% in Q4 2025, down 484851.0% YoY from N/an in Q4 2024, and down 26.34% on a QoQ basis from 18405.73% in Q4 2024.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Net Margin (2016 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 9 years of Net Margin data on file, last reported at 23254.24% in Q4 2025.
- Quarterly Net Margin fell 484851.0% year-over-year to 23254.24% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 15651.8% (down 768604.0% YoY) and the FY2025 annual result came in at 132642.37%, down 12467661.0% from the prior year.
- Net Margin declined to 23254.24% in Q4 2025, from 18405.73% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23254.24% in Q4 2025.
- A 4-year average of 3588.02% and a median of 1274.18% in 2023 frame the typical range for Net Margin.
- The widest YoY moves for Net Margin: up 1146706 bps in 2024, down 1697526 bps in 2024.
- Tracing AVTX's Net Margin over 4 years: stood at 29.68% in 2021, then sank by 4720 bps to 1430.47% in 2023, then slumped by 1187 bps to 18405.73% in 2024, then fell by 26 bps to 23254.24% in 2025.
- The last three Net Margin figures came in at 23254.24% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Avalo Therapeutics | 843.26 Mn | 843.26 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -23,254.24% |
| Dec 31, 2024 | -18,405.73% |
| Sep 30, 2024 | 9,251.81% |
| Dec 31, 2023 | -1,430.47% |
| Sep 30, 2023 | -2,215.25% |
| Jun 30, 2023 | -1,274.18% |
| Mar 31, 2023 | -2,095.79% |
| Dec 31, 2022 | -1,095.09% |
| Sep 30, 2022 | 21.35% |
| Jun 30, 2022 | -1,257.21% |
| Mar 31, 2022 | -1,879.88% |
| Dec 31, 2021 | -8,774.43% |
| Sep 30, 2021 | -1,288.52% |
| Jun 30, 2021 | -509.81% |
| Mar 31, 2021 | -6,486.26% |
| Dec 31, 2020 | -1,044.96% |
| Sep 30, 2020 | -1,211.43% |
| Jun 30, 2020 | -989.16% |
| Mar 31, 2020 | -765.21% |
| Dec 31, 2019 | 279.10% |